News
FDA approves GSK’s Jemperli for dMMR endometrial cancer
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli for the treatment of patients with advanced endometrial cancer with a specific biomarker.